Business Wire

FEELM

22.5.2023 13:54:26 CEST | Business Wire | Press release

Share
FEELM and RELX international Launch First Whole Chain Recycling Scheme for Disposable Vapes in the UK

World leading closed system solution provider FEELM has joined forces with leading vaping brand RELX to launch the UK vape industry’s first whole-chain recycling scheme for single use devices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005354/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FEELM Cooperates with RELX for the first industrial whole chain recycling scheme

The initiative aims to address the growing concerns surrounding single use products being thrown away by consumers and the environmental impact caused by them ending up in landfill.

It follows estimates from independent non-profit organization Material Focus that 1.3 million single use vape devices are discarded each week in the UK which, taken over a year, contain enough lithium to power 1,200 electric vehicles.

Also, based on market research by Opinium, around 168 million disposable vapes are bought annually in the UK, with half of those being thrown out with regular waste rather than being disposed of in a waste electricals recycling bin or being returned to the retailer.

This new initiative will see FEELM, the flagship brand of inhalation tech company SMOORE, team up with leading single use vape provider RELX to implement sustainability strategies which will benefit both their business partners, customers and the wider community.

The initiative involves a household collection system, a transparent recycling process and retailer partnerships to make it as easy as possible for consumers to participate.

Consumers can send their used vapes to FEELM either through pre-paid postage labels downloaded online or by visiting one of the retail partners. The household collection system simplifies the recycling process, making it more accessible to a broader audience.

To encourage consumers to participate in the recycling scheme, FEELM plans to introduce an incentive mechanism that boosts consumer engagement. For every ten used devices sent back, RELX provides a brand new RELX Magic Go disposable vape with FEELM Max technology. The FEELM Max boasts impressive performance and sets a new TPD-compliant industry benchmark, offering 800 puffs with its 2 ML capacity.

By fostering a recycling mindset and strengthening education around recycling, the company aims to create a more environmentally conscious community that actively participates in sustainable practices.

By offering a comprehensive and convenient recycling method, FEELM and RELX hope to raise the environmental awareness of end users, inspire trust in the recycling system and encourage consumers to play their part in helping protect the environment.

Delivering the Social Responsibility

Commenting on the recycling scheme, Johnny Zhang, Assistant President at FEELM said: “We firmly believe that disposables have a critical part to play in helping the UK achieve its smokefree aspirations. The industry needs to do much more in the environmental department, but it is starting to make headway.

“Our green innovation program is well underway, but we are now ramping it up significantly to ensure we don’t just help protect adult smokers’ lives but also the planet too.

“This commitment to making recycling more accessible demonstrates our dedication to corporate social responsibility and environmental sustainability. As this initiative gains traction, we hope it will serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in their sustainability efforts.”

Chris Aikens, Senior External Affairs Manager for Europe at RELX International, said: “We are pleased to be working with SMOORE on this project which highlights our commitment to the long-term sustainability of disposable devices. These products provide a useful tool to enable adult smokers to make the switch from combustible cigarettes and their full potential needs to be recognised. This recycling scheme will benefit both the planet and adult consumers.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005354/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye